Developments relevant to general practice and primary care — service changes, family-history guidance, and what's shifting in how genetics meets the front line.
20 stories · Last updated
The US Food and Drug Administration has licensed mFluSIva, Moderna's messenger RNA flu shot, marking the first regulatory approval of mRNA technology for influenza.
A major genome-wide study has expanded the known genetic architecture of hyperemesis gravidarum to ten risk genes, several of which implicate appetite and nausea regulation pathways.
A new briefing from the PHG Foundation at the University of Cambridge outlines recommendations for EU and national governments seeking to embed genomics-informed prevention into health systems.
Cancer Research UK's policy team examines whether commitments in the National Cancer Plan are sufficient to meet the ambition of expanding clinical trial access in the UK.
Columbia University researchers report that a specific genetic variant may accelerate heart valve damage in people with degenerative mitral regurgitation who also take SSRI antidepressants.
Cancer Research UK reports that new data provide the strongest evidence to date that the UK HPV vaccination programme is reducing not only cervical cancer incidence but cervical cancer mortality.
Michelle Sie Whitten of the Global Down Syndrome Foundation writes in STAT News that women receiving a prenatal Down syndrome diagnosis are routinely given outdated or incomplete information about life expectancy and quality of life.
A cross-cohort analysis of nearly 20,000 individuals from four British birth cohort studies shows that polygenic risk for high body mass index became a stronger predictor of observed BMI in cohorts born later into the obesity epidemic.
The world's first randomised trial of a multi-cancer early detection blood test did not meet its primary endpoint, though commentators argue the results carry important signals for the field of early-detection genomics.
Phase 3 results for Revolution Medicines' daraxonrasib show a 60% reduction in risk of death compared with standard chemotherapy, marking the first practice-changing advance for KRAS-mutant pancreatic cancer.
A preprint from Cold Spring Harbor Laboratory describes a 'dish-to-biobank' framework that connects controlled glucolipotoxicity stress in stem-cell-derived beta cells to population-scale type 2 diabetes genetics via the plasma proteome.
The UK National Screening Committee has endorsed a risk-stratified approach to prostate cancer screening, focusing on men who carry a BRCA2 pathogenic variant and have a relevant family history of cancer.
A study has identified heritable variants that appear to reduce responsiveness to GLP-1 receptor agonists in clinical trials, potentially explaining why a subset of patients fail to reach glycaemic targets.
New NHS England data show that mobile scanning units deployed at supermarkets, sports stadiums and high streets have detected 10,678 lung cancers, more than three-quarters at stages one or two.
A specialist First Opinion piece in STAT News draws three lessons from the world's first randomised trial of a multi-cancer early detection blood test, which did not meet its primary endpoint.
Cancer Research UK analysis shows melanoma incidence has reached its highest recorded level in the UK, raising questions about prevention, surveillance, and the role of genetic risk factors.
Nusinersen and risdiplam will be routinely available on the NHS in England following an evidence-collection access scheme, giving families with spinal muscular atrophy long-term certainty.
A PHG Foundation analysis highlights how genetic variants affecting red blood cell biology can cause HbA1c to misclassify diabetes risk, with disproportionate impact across ancestry groups.
A new systematic review published in 2026 concludes that prostate-specific antigen blood testing likely reduces the risk of death from prostate cancer, though over-diagnosis and over-treatment remain concerns.
A paper in Nature Medicine reports that Australia has passed legislation preventing life insurers from using genetic test results to discriminate against applicants — a significant regulatory development with implications for genetic testing uptake.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List